Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06758921

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries (BIO-OSCAR First)

The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

LKH Univ. -Klinikum Graz, Ambulanz für Angiologie, Graz, Austria

Loading trial locations.

About this study

This is a prospective, multicenter, all-comers observational study. Primary endpoint was procedural success (defined as a combination of successful primary target lesion crossing, residual stenosis of ≤30% following vessel preparation and before definite treatment) and absence of procedural complications (defined as target vessel perforation or rupture, acute occlusion, and distal embolization).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject ≥18 years old
  • Subject has provided written informed consent
  • Subject has Rutherford classification 2 to 6
  • Reference vessel diameter ≥2 and ≤7 mm
  • Target lesion(s) has stenosis >70% by visual assessment
  • Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.

Above the knee (ATK) group:

  • Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
  • At least one below-knee artery patent to the ankle
  • Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.

Below the knee (BTK) group:

  • Target lesions involve arteries below the tibial plateau
  • Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications

Exclusion criteria

  • Subject has a single target lesion that involves both ATK and BTK segments.
  • Subject not suitable for receiving endovascular procedures of lower limb arteries.
  • Prior planned major amputation in the target limb (i.e., above the ankle).
  • Subject with previous bypass surgery of target vessel.
  • History of any open surgical procedure within the past 30 days.
  • Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb.

Note: The inflow vessels can be treated on the day of the procedure.

  • Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis).
  • Subject under dialysis.
  • Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached.
  • Subject lacking capacity to provide informed consent.
  • Subject under judicial protection, tutorship, or curatorship (for France only).

Treatment and study plan

Oscar Peripheral Multifunctional Catheter

Device

Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon.

Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU).

Primary outcomes

  1. Oscar Procedural success rate

    Time frame: Index procedure

    combination of Oscar technical success and absence of serious procedural complications

Secondary outcomes

  1. Rate of (Serious) Adverse Device Effects (S)ADE

    Time frame: discharge (30 days)

    (Serious) Adverse Device Effects

  2. Rate of distal embolization

    Time frame: Index procedure

    Distal embolization

  3. Rate of target vessel rupture

    Time frame: Index procedure

    Target vessel rupture

  4. Rate of target vessel perforation

    Time frame: Index procedure

    Target vessel perforation

  5. Rate of target vessel acute occlusion

    Time frame: Index procedure

    Target vessel acute occlusion

  6. Rate of Oscar PTA balloon related flow-limiting dissections

    Time frame: Index procedure

    flow-limiting dissections defined as NHLBI grade ≥D

  7. Rate of peri-operative death (all-cause of death until discharge)

    Time frame: discharge (30 days)

    peri-operative death defined as all-cause of death until discharge

  8. Rate of unplanned major amputation

    Time frame: discharge (30 days)

    unplanned major amputation

  9. Oscar crossing success

    Time frame: Index procedure

    angiographic confirmation of successful placement of a guidewire into the distal true lumen with Oscar support catheter used together with the dilator and/ or Oscar PTA balloon, and without any additional crossing/re-entry device.

  10. Post-Oscar residual stenosis

    Time frame: Index procedure

    Post-Oscar residual stenosis (%)

  11. Final treatment residual stenosis (%) on the completion angiogram

    Time frame: Index procedure

    Final residual stenosis (%) on the completion angiogram

Study contacts

Contact information is provided by the study sponsor or research team.

Helene Kuissu, PharmD

CONTACT

[email protected]

+41 44 864 54 80

Sponsors and collaborators

Lead sponsor

Biotronik AG

Industry

Registry information

Official study title

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jan 6, 2025
Registry last updated
Jan 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.